Illumina, Inc. $ILMN Stock Holdings Increased by Illinois Municipal Retirement Fund

Illinois Municipal Retirement Fund increased its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 6.8% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 115,293 shares of the life sciences company’s stock after buying an additional 7,327 shares during the period. Illinois Municipal Retirement Fund’s holdings in Illumina were worth $31,553,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. BlackRock Inc. bought a new position in Illumina in the 2nd quarter valued at about $3,374,423,000. WCM Investment Management LLC lifted its position in Illumina by 45.5% during the first quarter. WCM Investment Management LLC now owns 5,923,173 shares of the life sciences company’s stock worth $715,579,000 after acquiring an additional 1,851,848 shares during the last quarter. Primecap Management Co. CA bought a new stake in shares of Illumina during the second quarter worth approximately $617,981,000. Janus Henderson Group PLC boosted its holdings in shares of Illumina by 1.4% during the first quarter. Janus Henderson Group PLC now owns 2,100,638 shares of the life sciences company’s stock worth $258,924,000 after acquiring an additional 29,094 shares during the period. Finally, Southpoint Capital Advisors LP grew its position in shares of Illumina by 20.0% in the first quarter. Southpoint Capital Advisors LP now owns 2,100,000 shares of the life sciences company’s stock valued at $258,846,000 after purchasing an additional 349,536 shares during the last quarter. Institutional investors and hedge funds own 89.42% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have recently weighed in on ILMN. Piper Sandler increased their target price on Illumina from $225.00 to $305.00 and gave the stock an “overweight” rating in a research note on Monday, September 28th. Zacks Research downgraded Illumina from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 1st. Argus boosted their price target on Illumina from $180.00 to $235.00 and gave the company a “buy” rating in a research note on Thursday, September 3rd. UBS Group raised Illumina from a “neutral” rating to a “buy” rating and upped their price objective for the company from $135.00 to $260.00 in a report on Wednesday, September 9th. Finally, Barclays increased their price objective on Illumina from $160.00 to $200.00 and gave the stock an “underweight” rating in a research report on Wednesday, October 7th. Ten analysts have rated the stock with a Buy rating, six have issued a Hold rating and three have given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $244.24.

Illumina Stock Performance

NASDAQ ILMN opened at $214.91 on Wednesday. The company has a quick ratio of 2.05, a current ratio of 2.63 and a debt-to-equity ratio of 0.57. The company has a market capitalization of $32.49 billion, a P/E ratio of 36.99, a P/E/G ratio of 3.00 and a beta of 1.46. Illumina, Inc. has a 12-month low of $112.65 and a 12-month high of $309.35. The firm has a 50-day moving average price of $249.27 and a two-hundred day moving average price of $178.77.

Illumina (NASDAQ:ILMN) last announced its earnings results on Thursday, October 29th. The life sciences company reported $1.62 EPS for the quarter, topping the consensus estimate of $1.36 by $0.26. Illumina had a net margin of 19.72% and a return on equity of 28.38%. The company had revenue of $1.17 billion for the quarter, compared to analysts’ expectations of $1.15 billion. During the same period last year, the firm earned $1.34 earnings per share. The business’s revenue for the quarter was up 4.2% on a year-over-year basis. Analysts anticipate that Illumina, Inc. will post 5.43 earnings per share for the current year.

Insider Activity

In related news, Director Keith Meister sold 50,000 shares of the stock in a transaction that occurred on Wednesday, November 4th. The stock was sold at an average price of $227.17, for a total transaction of $11,358,500.00. Following the sale, the director owned 488,917 shares of the company’s stock, valued at $111,067,274.89. This represents a 9.28% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Insiders sold 1,601,541 shares of company stock valued at $354,755,291 in the last three months. Insiders own 2.90% of the company’s stock.

Illumina Profile

Illumina, Inc. develops and supplies technologies used to analyze genetic variation and biological function. Its products include next-generation sequencing systems, microarrays, reagents and consumables, as well as software and related services that help customers generate and interpret genomic data. The company’s technology is used in applications such as medical and population research, genetic testing, drug development, and agricultural and environmental studies. Its customers include academic and government research institutions, hospitals and clinical laboratories, biotechnology and pharmaceutical companies, and other organizations around the world.